Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Share-based Compensation (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Share-based Compensation for 3 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 27.24% to $1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.8 million, a 2.28% decrease, with the full-year FY2025 number at $6.8 million, down 2.28% from a year prior.
  • Share-based Compensation was $1.6 million for Q4 2025 at Artiva Biotherapeutics, down from $1.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.2 million in Q4 2024 to a low of $1.4 million in Q3 2023.
  • A 3-year average of $1.7 million and a median of $1.6 million in 2025 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 56.9% in 2024, then dropped 27.24% in 2025.
  • Artiva Biotherapeutics' Share-based Compensation stood at $1.4 million in 2023, then soared by 56.9% to $2.2 million in 2024, then dropped by 27.24% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Share-based Compensation are $1.6 million (Q4 2025), $1.6 million (Q3 2025), and $1.5 million (Q2 2025).